Menu

Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer's Disease

Article |

Radiant660Geek 7mo ago
Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer's Disease

Muna Therapeutics, a clinical stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases,...

Comments (0)

Newest

No comments yet.